Mina Nicole Händel, Henning Keinke Andersen, Anja Ussing, Anne Virring, Poul Jennum, Nanette Mol Debes, Torben Laursen, Lone Baandrup, Christina Gade, Jette Dettmann, Jonas Holm, Camilla Krogh, Kirsten Birkefoss, Simon Tarp, Mette Bliddal, Henriette Edemann-Callesen
8 min
Melatonin is increasingly prescribed to treat chronic insomnia in children and adolescents. Despite this widespread use, the long-term safety profile of the hormone remains unclear, particularly regarding potential impacts on pubertal development and bone metabolism. This systematic review aimed to provide clinicians and guideline developers with a robust assessment of both short-term adverse events and long-term developmental outcomes.
The researchers conducted a systematic search of databases, including PubMed, Embase, Cinahl, and PsycINFO, for studies covering children and adolescents (aged 5–20 years) with chronic insomnia. The study design followed the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) framework to assess the certainty of evidence. The analysis included 22 randomized controlled trials (1,350 participants) to evaluate serious and non-serious adverse events and four observational studies (105 participants) to evaluate long-term pubertal development.
The meta-analysis indicated that melatonin does not significantly increase the risk of serious adverse events compared to placebo. However, the data revealed an increased risk of non-serious adverse events (e.g., headache, nausea, fatigue, and mood changes). Regarding long-term development, the studies provided very low certainty evidence; three studies found no significant influence on puberty after 2–4 years of treatment, whereas one study suggested a potential delay in pubertal timing following longer durations of treatment (>7 years). Crucially, no studies were identified that investigated the relationship between melatonin treatment and bone health in this population.
Given the rising prevalence of off-label and self-prescribed melatonin use in young populations, the identified knowledge gap is significant. The findings suggest that while melatonin is generally safe from severe clinical outcomes in the short term, clinicians should not be complacent. The uncertainty surrounding long-term impacts on the developing endocrine system and potential non-serious side effects underscores the urgent need for more rigorous, long-term studies to inform clinical practice and pediatric health guidelines.
Background: Currently, melatonin is used to treat children and adolescents with insomnia without knowing the full extent of the short-term and long-term consequences. Our aim was to provide clinicians and guideline panels with a systematic assessment of serious-and non-serious adverse events seen in continuation of melatonin treatment and the impact on pubertal development and bone health following long-term administration in children and adolescents with chronic insomnia. Methods: We searched PubMed, Embase, Cinahl and PsycINFO via Ovid, up to March 17, 2023, for studies on melatonin treatment among children and adolescents (aged 5-20 years) with chronic insomnia. The language was restricted to English, Danish, Norwegian, and Swedish. Outcomes were non-serious adverse events and serious adverse events assessed 2-4 weeks after initiating treatment and pubertal development and bone health, with no restriction on definition or time of measurement. Observational studies were included for the assessment of long-term outcomes, and serious and non-serious adverse events were assessed via randomised studies. The certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation (GRADE). The protocol is registered with the Danish Health Authority. Findings: = 47%). Three studies reported little or no influence on pubertal development following 2-4 years of treatment, whereas one study registered a potential delay following longer treatment durations (>7 years). These findings need further evaluation due to several methodological limitations. Interpretation: Children who use melatonin are likely to experience non-serious adverse events, yet the actual extent to which melatonin leads to non-serious adverse events and the long-term consequences remain uncertain. This major gap of knowledge on safety calls for caution against complacent use of melatonin in children and adolescents with chronic insomnia and for more research to inform clinicians and guideline panels on this key issue. Funding: The Danish Health Authority. The Parker Institute, Bispebjerg and Frederiksberg Hospital, supported by the Oak Foundation.
Alex: Let’s take the randomised evidence first. How large was the pool, and who was actually represented?
Sam: The review included twenty-two randomised studies reporting adverse events. Together, they involved about thirteen hundred and fifty participants. Most studies involved young people with underlying conditions, including autism, attention difficulties, or other neurological and developmental disorders.
Alex: That population matters if someone wants to apply the results to otherwise healthy children. Were the treatments themselves fairly consistent?
Sam: No. Doses, treatment lengths, and formulations varied. The trials were short, ranging from a week to a few months, so they cannot establish what happens after years of use.
Alex: What did combining those trials show about serious events? That seems the first place someone might look for reassurance.
Sam: The pooled comparison did not show an increase with melatonin versus placebo. Serious events include outcomes such as death, hospitalisation, or significant disability. The authors rated that evidence as moderate certainty, rather than high certainty, because the estimate was imprecise.
Alex: So “no increase detected” is fair, but “serious harm ruled out” would go beyond the evidence.
Sam: It would. The uncertainty around the estimate leaves room for differences the studies could not resolve. And this is reassurance within short trials, not a statement about lifelong safety.
Alex: What changed when they looked at non-serious adverse events? And “non-serious” doesn’t necessarily mean irrelevant to daily life.
Sam: The pooled results showed an increase with melatonin. On the absolute scale, that was about six additional participants experiencing an event per hundred treated, compared with placebo. Reported events included headache, nausea, fatigue or drowsiness, dizziness, and gastrointestinal problems.
Alex: That is easier to interpret than a relative increase alone. But does the pooled result establish that melatonin caused every symptom on that list?
Sam: No. The comparison concerns the overall number of participants reporting events, not proof that each listed symptom was caused by treatment. Confidence in the overall increase was moderate, while the exact size remained uncertain.
Alex: How consistently did the trials look for these events? A symptom checklist and a passing question at follow-up could produce different records.
Sam: That is a central weakness. The authors say systematic adverse-event assessment was rare, and complete reporting of event types and frequencies was rarer still. Some studies reported many events; others reported none in either group.
Alex: So part of the variation may concern how safety was investigated, not simply how participants responded. What about the longer-term evidence?
Sam: Here the evidence base shrinks to a handful of observational studies. After roughly two to four years of treatment, studies reported little or no apparent influence on puberty. A later follow-up suggested delayed timing after an average of about seven years.
Alex: That sounds like a possible duration effect. But a later signal could also reflect who remained in follow-up or how puberty was measured.
Sam: The authors call the duration interpretation speculative. These were small studies with serious risks of bias, including confounding and missing follow-up data. Some reports also followed the same population over time, rather than providing independent replication.
Alex: What did measuring puberty involve? That seems especially important when the proposed effect is a shift in timing.
Sam: Only one study used a physician-rated Tanner score, a rating of physical stages of puberty. Other assessments relied on self-report, questionnaires, or interviews with participants or parents. Comparisons sometimes came from previously published population data rather than a concurrently followed group.
Alex: Those methods might flag a question, but they make a confident developmental conclusion difficult. Were the authors able to combine them statistically?
Sam: They were not. The measurements and reporting differed too much for a meaningful pooled estimate, so the review described the studies separately. Its certainty rating for puberty was very low.
Alex: And for bones, was the conclusion similarly uncertain, or was there no eligible evidence at all?
Sam: No eligible studies reported bone mineral density or fracture risk. That means the review cannot establish either harm or reassurance for those outcomes. An empty evidence base is not evidence that nothing happens.
Alex: Given those gaps, does the review argue against melatonin treatment altogether, or against treating its safety as settled?
Sam: Against complacent use. The document identifies non-drug approaches as first-line treatment for childhood insomnia, with medication considered after those strategies have been tried. But this review assesses safety; it does not itself supply a complete comparison of treatment benefits and harms.
Alex: Who should read the full document, then, and where should they start?
Sam: Clinicians, guideline developers, and researchers studying paediatric sleep or development should read it. Start with the Results synthesis and the certainty assessment: they show where pooled comparisons are possible and where the evidence becomes fragile. Then read the Discussion’s account of puberty measurement and incomplete adverse-event reporting.
Alex: And for someone who only needs the conclusion to carry into a conversation with colleagues?
Sam: This review found more non-serious events with melatonin, without a detected increase in serious events during short trials. Long-term developmental safety remains unresolved. The line to remember is: short-term reassurance is not long-term safety.
Alex: Keep that distinction in mind when reading the next safety claim.